GlassScriptPhysician profile
Charles R Inners
NPI 1740251784
$620.53
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $477 · 2020: $144.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $239.83 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.41 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $60.40 | 2019 | |
| Mylan Specialty L.P. | $52.70 | 2019 | |
| Biofire Diagnostics, LLC | $46.81 | 2020 | |
| Jazz Pharmaceuticals INC. | $28.46 | 2019 | |
| Advanced Respiratory, INC | $27.35 | 2019 | |
| Genzyme Corporation | $20.41 | 2020 | |
| United Therapeutics Corporation | $17.60 | 2019 | |
| Resmed Corp | $17.59 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $15.26 | 2020 | |
| Alexion Pharmaceuticals, INC. | $13.60 | 2019 | |
| Grifols USA, LLC | $13.11 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Inners listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.